Zobrazeno 1 - 10
of 104
pro vyhledávání: '"IDH2 mutation"'
Autor:
Chien‐Chin Lin, Chi‐Yuan Yao, Yu‐Hung Wang, Yueh‐Chwen Hsu, Chang‐Tsu Yuan, Tsung‐Chih Chen, Chia‐Lang Hsu, Sze‐Hwei Lee, Jhih‐Yi Lee, Pin‐Tsen Shih, Chein‐Jun Kao, Po‐Han Chuang, Yuan‐Yeh Kuo, Hsin‐An Hou, Wen‐Chien Chou, Hwei‐Fang Tien
Publikováno v:
eJHaem, Vol 5, Iss 4, Pp 738-748 (2024)
Abstract Introduction IDH2 mutation is an unfavorable prognostic factor in patients with primary myelofibrosis (PMF) but its effect on myelofibrosis (MF) remains largely unclear. Methods In this study, we aimed to elucidate the roles of IDH2 mutation
Externí odkaz:
https://doaj.org/article/fa92d941b488439f9510b04086ba0152
Autor:
Kensuke Tateishi, Yohei Miyake, Taishi Nakamura, Hiromichi Iwashita, Takahiro Hayashi, Akito Oshima, Hirokuni Honma, Hiroaki Hayashi, Kyoka Sugino, Miyui Kato, Kaishi Satomi, Satoshi Fujii, Takashi Komori, Tetsuya Yamamoto, Daniel P. Cahill, Hiroaki Wakimoto
Publikováno v:
Acta Neuropathologica Communications, Vol 11, Iss 1, Pp 1-13 (2023)
Abstract In IDH-mutant astrocytoma, IDH2 mutation is quite rare and biological mechanisms underlying tumor progression in IDH2-mutant astrocytoma remain elusive. Here, we report a unique case of IDH2 mutant astrocytoma, CNS WHO grade 3 that developed
Externí odkaz:
https://doaj.org/article/bbe8b7243e7e40e29827ce3987261302
Autor:
Yusuke Daido, Hiroyuki Sugiura, Tatsunori Ishikawa, Taiga Kuroi, Sachiyo Okamoto, Naho Nomura, Taro Masunari, Nobuo Sezaki, Yasuhito Nannya, Seishi Ogawa, Mitsune Tanimoto
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 999-1006 (2023)
Venetoclax and azacitidine combination therapy (VEN+AZA) is a promising novel therapy for elderly or unfit patients with acute myeloid leukemia (AML). Recently, VEN+AZA with subsequent allo-hematopoietic stem cell transplantation has been reported, a
Externí odkaz:
https://doaj.org/article/82eb6e7f3dbb47e49f5bfcaf6e14197d
Autor:
Syed Muhammad Waqar Haider, Mehwish Zehra, Nikesh N Shah, Eduardo M Sotomayor, David M Swoboda
Publikováno v:
Leukemia Research Reports, Vol 21, Iss , Pp 100461- (2024)
A 67-year-old female came to Tampa General Hospital with Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) featuring an intriguing combination of mutations, including NPM1 and IDH2 mutations. Novel combination therapy with azacitidi
Externí odkaz:
https://doaj.org/article/90e7c5ede15d442d8b469d7d5866f487
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Current Oncology, Vol 29, Iss 4, Pp 2550-2563 (2022)
Laser interstitial thermal therapy (LITT) has become an increasingly utilized alternative to surgical resection for the treatment of glioma in patients. However, treatment outcomes in isocitrate dehydrogenase 1 and 2 (IDH1/2) mutant glioma, specifica
Externí odkaz:
https://doaj.org/article/8550a66e29ac49ddac896f7b108ca0fb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Human Pathology Reports, Vol 26, Iss , Pp 300575- (2021)
Maffucci syndrome is a rare non-familial condition characterized by enchondromas/chondrosarcomas and soft tissue hemangiomas. Multiple fibroadenomas in young women has been described in patients with Maffucci syndrome. IDH1/2 somatic mutations have b
Externí odkaz:
https://doaj.org/article/9ccbbc184611475db747114443bb2fa3
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Isocitrate dehydrogenase (IDH) is a key metabolic enzyme catalyzing the interconversion of isocitrate to α-ketoglutarate (α-KG). Mutations in IDH lead to loss of normal enzymatic activity and gain of neomorphic activity that irreversibly converts
Externí odkaz:
https://doaj.org/article/8dcefe4504b74aefa1c86c70c05838a3